Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $30.4 million.

  • Xeris Biopharma Holdings' Accumulated Expenses rose 2891.31% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year increase of 2891.31%. This contributed to the annual value of $27.7 million for FY2024, which is 1789.03% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Accumulated Expenses is $30.4 million, which was up 2891.31% from $25.0 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Accumulated Expenses registered a high of $49.1 million during Q4 2021, and its lowest value of $19.1 million during Q3 2023.
  • Its 5-year average for Accumulated Expenses is $27.8 million, with a median of $23.5 million in 2024.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Accumulated Expenses surged by 20882.67% in 2021 and then crashed by 4941.79% in 2023.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Accumulated Expenses stood at $49.1 million in 2021, then decreased by 25.06% to $36.8 million in 2022, then tumbled by 36.09% to $23.5 million in 2023, then increased by 17.89% to $27.7 million in 2024, then rose by 9.5% to $30.4 million in 2025.
  • Its last three reported values are $30.4 million in Q3 2025, $25.0 million for Q2 2025, and $20.0 million during Q1 2025.